208. #VESSIE IMMUNOTHÉRAPIE PÉRIOPÉRATOIRE DANS LES TVIM : RATIONNEL ET RÉSULTATS - DOCTEUR GAUTIER MARCQ

208. #VESSIE IMMUNOTHÉRAPIE PÉRIOPÉRATOIRE DA...

AFUFAFUF

Up next

217. LASER DOPÉS AU THULIUM : AVANTAGES ET PERSPECTIVES DANS LA PRISE EN CHARGE DE CALCULS URINAIRES - DR PANTHIER

217. LASER DOPÉS AU THULIUM : AVANTAGES ET PERSPECTIVES DANS LA PRISE EN CHARGE DE CALCULS URINAIRES - DR PANTHIERQu'est-ce qu'un laser thulium ?Quels sont les avantages du laser thulium fibré par rapport au laser holmium-YAG ?Quels sont les lasers recommandés en 2024 pour traite ...  Show more

 . 10min 59sec
216. IDENTIFICATION ET PRISE EN CHARGE DES MALADIES LITHIASIQUES HEREDITAIRES - PROFESSEUR HAYMANN

216. IDENTIFICATION ET PRISE EN CHARGE DES MALADIES LITHIASIQUES HEREDITAIRES - PROFESSEUR HAYMANNQuand faut-il suspecter les maladies lithiasiques héréditaires ? Comment les identifier ? De quels outils dispose t-on et quelles sont les recommandations diététiques et thérapeutiqu ...  Show more

 . 8min 37sec

Recommended Episodes

40 - Infectious Cancer Therapy
The Curious Clinicians

The Curious Clinicians examine why we use a bacterial vaccine (BCG, an attenuated form of mycobacterium bovis) to treat an unrelated malignancy (bladder cancer). Check out the show notes here. Click here to obtain AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance ...  Show more

 . 16min 12sec
Ep. 267 Sequencing Therapies in NMIBC Management with Dr. Mark Tyson and Dr. Suzanne Merrill
BackTable Urology

New FDA-approved therapies for BCG-refractory non-muscle invasive bladder cancer (NMIBC)–where do they fit in the treatment algorithm, and how do you administer them? This installment of the 2025 NMIBC Creator Weekend™ series features host Dr. Bogdana Schmidt, assistant professor ...  Show more

 . 1h 0min
AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer
AUAUniversity

AUA Guidelines: Treatment Of Non - Metastatic Muscle - Invasive Bladder Cancer Guest: Jeffrey M Holzbeierlein, MD Outline: Segment #1: Guideline Statement 9-Patients who have not received cisplatin-based NAC and have pT3-4 and/or N= disease at cystectomy should receive adjuvant c ...  Show more

 . 35min 22sec
Ep. 178 ASCO 2024: Game-Changing GU Oncology Updates in Bladder and Kidney Cancers with Dr. Sumanta Pal and Dr. Petros Grivas
BackTable Urology

Stay up-to-date on the latest advancements and treatment strategies in the field of genitourinary oncology. In this episode of BackTable Urology, guest host Dr. Bogdana Schmidt, a urologic oncologist from the University of Utah, discusses takeaways from ASCO 2024 with Dr. Petros ...  Show more

 . 57min 23sec